ASX - By Stock
|
CYP |
Re:
Ann: Investor Presentation
|
|
pfeifer1982
|
454 |
71K |
7 |
12/06/24 |
12/06/24 |
ASX - By Stock
|
454
|
71K
|
7
|
|
ASX - By Stock
|
CYP |
Re:
Ann: Investor Presentation
|
|
pfeifer1982
|
454 |
71K |
7 |
12/06/24 |
12/06/24 |
ASX - By Stock
|
454
|
71K
|
7
|
|
ASX - By Stock
|
CYP |
Re:
Ann: Investor Presentation
|
|
pfeifer1982
|
454 |
71K |
10 |
11/06/24 |
11/06/24 |
ASX - By Stock
|
454
|
71K
|
10
|
|
ASX - By Stock
|
CYP |
Re:
Ann: Investor Presentation
|
|
pfeifer1982
|
454 |
71K |
9 |
11/06/24 |
11/06/24 |
ASX - By Stock
|
454
|
71K
|
9
|
|
ASX - By Stock
|
CYP |
Re:
Ann: Investor Presentation
|
|
pfeifer1982
|
454 |
71K |
8 |
11/06/24 |
11/06/24 |
ASX - By Stock
|
454
|
71K
|
8
|
|
ASX - By Stock
|
CYP |
Re:
Ann: Investor Presentation
|
|
pfeifer1982
|
454 |
71K |
14 |
09/06/24 |
09/06/24 |
ASX - By Stock
|
454
|
71K
|
14
|
|
ASX - By Stock
|
CYP |
Re:
Ann: Investor Presentation
|
|
pfeifer1982
|
454 |
71K |
8 |
08/06/24 |
08/06/24 |
ASX - By Stock
|
454
|
71K
|
8
|
|
ASX - By Stock
|
CYP |
Re:
Ann: Investor Presentation
|
|
pfeifer1982
|
454 |
71K |
11 |
07/06/24 |
07/06/24 |
ASX - By Stock
|
454
|
71K
|
11
|
|
ASX - By Stock
|
CYP |
Re:
Ann: Investor Presentation
|
|
pfeifer1982
|
454 |
71K |
11 |
07/06/24 |
07/06/24 |
ASX - By Stock
|
454
|
71K
|
11
|
|
ASX - By Stock
|
CHM |
Re:
Ann: 1st patient treated in ADVENT-AML Phase 1b clinical trial
|
|
pfeifer1982
|
73 |
25K |
15 |
06/06/24 |
06/06/24 |
ASX - By Stock
|
73
|
25K
|
15
|
|
ASX - By Stock
|
CHM |
Re:
Ann: 1st patient treated in ADVENT-AML Phase 1b clinical trial
|
|
pfeifer1982
|
73 |
25K |
1 |
05/06/24 |
05/06/24 |
ASX - By Stock
|
73
|
25K
|
1
|
|
ASX - By Stock
|
CHM |
Re:
Ann: 1st patient treated in ADVENT-AML Phase 1b clinical trial
|
|
pfeifer1982
|
73 |
25K |
7 |
05/06/24 |
05/06/24 |
ASX - By Stock
|
73
|
25K
|
7
|
|
ASX - By Stock
|
CHM |
Re:
Ann: 1st patient treated in ADVENT-AML Phase 1b clinical trial
|
|
pfeifer1982
|
73 |
25K |
8 |
04/06/24 |
04/06/24 |
ASX - By Stock
|
73
|
25K
|
8
|
|
ASX - By Stock
|
CYP |
Re:
Ann: Investor Presentation
|
|
pfeifer1982
|
454 |
71K |
9 |
02/06/24 |
02/06/24 |
ASX - By Stock
|
454
|
71K
|
9
|
|
ASX - By Stock
|
CYP |
Re:
Ann: Investor Presentation
|
|
pfeifer1982
|
454 |
71K |
11 |
02/06/24 |
02/06/24 |
ASX - By Stock
|
454
|
71K
|
11
|
|
ASX - By Stock
|
CYP |
Re:
Ann: Investor Presentation
|
|
pfeifer1982
|
454 |
71K |
10 |
02/06/24 |
02/06/24 |
ASX - By Stock
|
454
|
71K
|
10
|
|
ASX - By Stock
|
CYP |
Re:
Ann: Investor Presentation
|
|
pfeifer1982
|
454 |
71K |
13 |
02/06/24 |
02/06/24 |
ASX - By Stock
|
454
|
71K
|
13
|
|
ASX - By Stock
|
CYP |
Re:
Ann: Investor Presentation
|
|
pfeifer1982
|
454 |
71K |
16 |
31/05/24 |
31/05/24 |
ASX - By Stock
|
454
|
71K
|
16
|
|
ASX - By Stock
|
MSB |
Re:
Ann: FDA Notifies Clinical Data Sufficient for Refiling aGVHD BLA
|
|
pfeifer1982
|
1.0K |
379K |
1 |
27/05/24 |
27/05/24 |
ASX - By Stock
|
1.0K
|
379K
|
1
|
|
ASX - By Stock
|
CYP |
Re:
Ann: Investor Presentation
|
|
pfeifer1982
|
454 |
71K |
12 |
24/05/24 |
24/05/24 |
ASX - By Stock
|
454
|
71K
|
12
|
|
ASX - By Stock
|
CYP |
Re:
Ann: Investor Presentation
|
|
pfeifer1982
|
454 |
71K |
12 |
23/05/24 |
23/05/24 |
ASX - By Stock
|
454
|
71K
|
12
|
|
ASX - By Stock
|
CYP |
Re:
Ann: Further GvHD Clinical Data Published in Nature Medicine
|
|
pfeifer1982
|
12 |
3.0K |
16 |
23/05/24 |
23/05/24 |
ASX - By Stock
|
12
|
3.0K
|
16
|
|
ASX - By Stock
|
CYP |
Re:
Ann: Appendix 3Y-Dr Geoffrey Brooke
|
|
pfeifer1982
|
41 |
7.4K |
8 |
20/05/24 |
20/05/24 |
ASX - By Stock
|
41
|
7.4K
|
8
|
|
ASX - By Stock
|
CYP |
Re:
Ann: Appendix 3Y-Dr Geoffrey Brooke
|
|
pfeifer1982
|
41 |
7.4K |
8 |
20/05/24 |
20/05/24 |
ASX - By Stock
|
41
|
7.4K
|
8
|
|
ASX - By Stock
|
CYP |
Re:
Ann: Appendix 3Y-Dr Geoffrey Brooke
|
|
pfeifer1982
|
41 |
7.4K |
12 |
19/05/24 |
19/05/24 |
ASX - By Stock
|
41
|
7.4K
|
12
|
|
ASX - By Stock
|
CYP |
Re:
Ann: Appendix 3Y-Dr Geoffrey Brooke
|
|
pfeifer1982
|
41 |
7.4K |
3 |
17/05/24 |
17/05/24 |
ASX - By Stock
|
41
|
7.4K
|
3
|
|
ASX - By Stock
|
CHM |
Re:
Ann: 1st patient dosed in CHM 0201 Vactosertib trial
|
|
pfeifer1982
|
16 |
8.2K |
16 |
15/05/24 |
15/05/24 |
ASX - By Stock
|
16
|
8.2K
|
16
|
|
ASX - By Stock
|
CYP |
Re:
Ann: Investor Presentation
|
|
pfeifer1982
|
454 |
71K |
13 |
11/05/24 |
11/05/24 |
ASX - By Stock
|
454
|
71K
|
13
|
|
ASX - By Stock
|
CYP |
Re:
Ann: DFU Clinical Trial Enrolment Complete
|
|
pfeifer1982
|
28 |
7.3K |
10 |
17/04/24 |
17/04/24 |
ASX - By Stock
|
28
|
7.3K
|
10
|
|
ASX - By Stock
|
CHM |
Re:
Charting Only
|
|
pfeifer1982
|
449 |
156K |
8 |
10/04/24 |
10/04/24 |
ASX - By Stock
|
449
|
156K
|
8
|
|
ASX - By Stock
|
CYP Biotech |
Timelines
|
|
pfeifer1982
|
4 |
1.3K |
24 |
08/04/24 |
08/04/24 |
ASX - By Stock
|
4
|
1.3K
|
24
|
|
ASX - By Stock
|
MSB |
Re:
Ann: FDA Notifies Clinical Data Sufficient for Refiling aGVHD BLA
|
|
pfeifer1982
|
1.0K |
379K |
12 |
06/04/24 |
06/04/24 |
ASX - By Stock
|
1.0K
|
379K
|
12
|
|
ASX - By Stock
|
MSB |
Re:
Ann: FDA Notifies Clinical Data Sufficient for Refiling aGVHD BLA
|
|
pfeifer1982
|
1.0K |
379K |
50 |
05/04/24 |
05/04/24 |
ASX - By Stock
|
1.0K
|
379K
|
50
|
|
ASX - By Stock
|
CYP |
Re:
Ann: First Patient Treated in Phase 2 GvHD Trial
|
|
pfeifer1982
|
61 |
12K |
14 |
05/04/24 |
05/04/24 |
ASX - By Stock
|
61
|
12K
|
14
|
|
ASX - By Stock
|
CYP |
Re:
Ann: First Patient Treated in Phase 2 GvHD Trial
|
|
pfeifer1982
|
61 |
12K |
7 |
22/03/24 |
22/03/24 |
ASX - By Stock
|
61
|
12K
|
7
|
|
ASX - By Stock
|
CYP |
Re:
Ann: First Patient Treated in Phase 2 GvHD Trial
|
|
pfeifer1982
|
61 |
12K |
12 |
22/03/24 |
22/03/24 |
ASX - By Stock
|
61
|
12K
|
12
|
|
ASX - By Stock
|
CHM |
Re:
Ann: Clinical milestones for 2024 & 2023 successes highlighted
|
|
pfeifer1982
|
26 |
9.5K |
15 |
20/03/24 |
20/03/24 |
ASX - By Stock
|
26
|
9.5K
|
15
|
|
ASX - By Stock
|
CYP |
Re:
The Phase I/IIb Nereid Study Is Now Registered
|
|
pfeifer1982
|
19 |
3.3K |
10 |
12/03/24 |
12/03/24 |
ASX - By Stock
|
19
|
3.3K
|
10
|
|
ASX - By Stock
|
CYP |
Re:
Going forward...
|
|
pfeifer1982
|
2.1K |
691K |
8 |
12/03/24 |
12/03/24 |
ASX - By Stock
|
2.1K
|
691K
|
8
|
|
ASX - By Stock
|
CYP |
Re:
The Phase I/IIb Nereid Study Is Now Registered
|
|
pfeifer1982
|
19 |
3.3K |
8 |
12/03/24 |
12/03/24 |
ASX - By Stock
|
19
|
3.3K
|
8
|
|
ASX - By Stock
|
CYP |
The Phase I/IIb Nereid Study Is Now Registered
|
|
pfeifer1982
|
19 |
3.3K |
18 |
09/03/24 |
09/03/24 |
ASX - By Stock
|
19
|
3.3K
|
18
|
|
ASX - By Stock
|
CYP |
Re:
Ann: First Patient Treated in Phase 2 GvHD Trial
|
|
pfeifer1982
|
61 |
12K |
10 |
07/03/24 |
07/03/24 |
ASX - By Stock
|
61
|
12K
|
10
|
|
ASX - By Stock
|
CYP |
Re:
Ann: Quarterly Activity Report & Appendix 4C
|
|
pfeifer1982
|
21 |
5.7K |
19 |
30/01/24 |
30/01/24 |
ASX - By Stock
|
21
|
5.7K
|
19
|
|
ASX - By Stock
|
MSB |
Re:
banter and General Discussion
|
|
pfeifer1982
|
9.8K |
2.9M |
12 |
10/01/24 |
10/01/24 |
ASX - By Stock
|
9.8K
|
2.9M
|
12
|
|
ASX - By Stock
|
CHM |
Re:
Chimeric: Media Thread
|
|
pfeifer1982
|
703 |
284K |
6 |
09/01/24 |
09/01/24 |
ASX - By Stock
|
703
|
284K
|
6
|
|
ASX - By Stock
|
MSB |
Re:
banter and General Discussion
|
|
pfeifer1982
|
9.8K |
2.9M |
13 |
08/01/24 |
08/01/24 |
ASX - By Stock
|
9.8K
|
2.9M
|
13
|
|
ASX - By Stock
|
MSB |
Re:
banter and General Discussion
|
|
pfeifer1982
|
9.8K |
2.9M |
7 |
08/01/24 |
08/01/24 |
ASX - By Stock
|
9.8K
|
2.9M
|
7
|
|
ASX - By Stock
|
CYP |
Re:
Ann: Initial Results in First 16 DFU Patients Expected in Q1 2024
|
|
pfeifer1982
|
37 |
12K |
17 |
06/01/24 |
06/01/24 |
ASX - By Stock
|
37
|
12K
|
17
|
|
ASX - By Stock
|
CHM |
Re:
Ann: 1st patient dosed in CHM 0201 Vactosertib trial
|
|
pfeifer1982
|
16 |
8.2K |
5 |
04/01/24 |
04/01/24 |
ASX - By Stock
|
16
|
8.2K
|
5
|
|
ASX - By Stock
|
CHM |
Re:
Ann: FDA clearance of IND for CHM 2101
|
|
pfeifer1982
|
75 |
23K |
12 |
02/01/24 |
02/01/24 |
ASX - By Stock
|
75
|
23K
|
12
|
|